Comprehensive ReviewK-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review
References (89)
- et al.
The Ras/Raf/MAPK pathway
J Thorac Oncol
(2006) - et al.
Understanding ras: ‘it ain't over ‘til it's over’
Trends Cell Biol
(2000) - et al.
Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of Ras
J Lipid Res
(2006) Cell signaling by receptor tyrosine kinases
Cell
(2000)Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity
Cell Signal
(2001)- et al.
PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond
Trends Biochem Sci
(1997) Ras signalling and apoptosis
Curr Opin Genet Dev
(1998)- et al.
The protein kinase B/Akt signalling pathway in human malignancy
Cell Signal
(2002) PI 3-kinase, akt and cell survival
Semin Cell Dev Biol
(2004)- et al.
Identification of a novel ras-regulated proapoptotic pathway
Curr Biol
(2002)
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context
Cancer Cell
Identification of bronchioalveolar stem cells in normal lung and lung cancer
Cell
Stem cells for lung cancer?
Cell
Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients
Cancer Lett
Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers
Eur J Cancer
Prognostic factors in non-small cell lung cancer: a decade of progress
Chest
Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?
Lung Cancer
Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in eastern cooperative oncology group (ECOG) trial E3590
Lung Cancer
The dark side of ras: regulation of apoptosis
Oncogene
Blocking oncogenic ras signaling for cancer therapy
J Natl Cancer Inst
Ras plasma membrane signalling platforms
Biochem J
Compartmentalized ras/mapk signaling
Annu Rev Immunol
Targeting RAS signalling pathways in cancer therapy
Nat Rev Cancer
GTPases and T cell activation
Immunol Rev
The TAO of MEKK
Front Biosci
Suppression of c-myc-induced apoptosis by ras signalling through PI(3)K and PKB
Nature
Ras/MEK signaling suppresses myc-dependent apoptosis in cells transformed by c-myc and activated ras
Oncogene
Suppression of ras-induced apoptosis by the rac GTPase
Mol Cell Biol
PI3K/Akt signalling pathway and cancer
Cancer Treat Rev
PI3K/Akt/mTOR pathway as a target for cancer therapy
Anticancer Drugs
The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance
Biochim Biophys Acta
NF-kappaB in cancer: from innocent bystander to major culprit
Nat Rev Cancer
Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs
Nat Rev Cancer
NF-kappaB blockade and oncogenic ras trigger invasive human epidermal neoplasia
Nature
Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3
Nat Genet
The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation
Mol Cell Biol
Ras GTPases: integrins' friends or foes?
Nat Rev Mol Cell Biol
Oncogenes as inducers of tumor angiogenesis
Cancer Metastasis Rev
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis
Cancer Res
The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers
Int J Oncol
The relationship between microvessel count and the expression of vascular endothelial growth factor, p53, and K-ras in non-small cell lung cancer
J Korean Med Sci
Regulation of vascular endothelial growth factor by the wnt and K-ras pathways in colonic neoplasia
Cancer Res
Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA
Cancer Res
Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells
Cancer Gene Ther
Cited by (200)
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
2021, Lung CancerCitation Excerpt :The transversion mutations G12C and G12 V (substituting a pyrimidine for a purine or vice versa) are more prevalent in smokers, while the transition mutations G12D and G12S (substituting purine for purine or pyrimidine for pyrimidine) are more prevalent in never-smokers [reviewed in 8,13]. Contradictory results on the prognostic value of KRAS mutations in NSCLC have been published [8,14,15] and similarly, the association of different KRAS mutation subtypes with clinical outcomes remains unclear [16]. The published results on the prognostic value of KRAS G12C mutations also vary greatly, probably due to different inclusion criteria and methodologies: a small, retrospective study in routine care in China reported better progression-free-survival (PFS) for patients with advanced NSCLC and KRAS G12C mutations, compared to non-G12C mutations [17].
Mechanisms of Fritillariae Thunbergii Flos in lung cancer treatment from a systems pharmacology perspective
2021, Journal of EthnopharmacologyAn Unusual Presentation of Aggressive Primary Invasive Adenocarcinoma of Lung
2021, American Journal of the Medical SciencesCitation Excerpt :Further studies should be done to unveil the reason behind gender differences in NSCLC with EGFR mutations. Kirsten rat sarcoma (KRAS) gene mutations can be present in approximately 15 to 25 percent of lung adenocarcinomas.21 In patients with KRAS-mutated NSCLC, programmed cell death ligand 1 (PD-L1) expression (44 percent) was reportedly higher in patients with smoking history versus former (20 percent) or never smokers (13 percent).18
Direct GDP-KRAS<sup>G12C</sup> inhibitors and mechanisms of resistance: the tip of the iceberg
2023, Therapeutic Advances in Medical Oncology
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1525-7304, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.